Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hyperreflexia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Hyperreflexia. Displaying page 1 of 1.
    EudraCT Number: 2012-003178-22 Sponsor Protocol Number: 905-CL-074 Start Date*: 2013-04-17
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Phase 3, Open-Label, Baseline-controlled, Multi-center, Sequential Dose -Titration Study to Assess the Pharmacokinetics, Long-Term Efficacy and Safety of Solifenacin Succinate Suspension in Child...
    Medical condition: Neurogenic Detrusor Overactivity (NDO)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10012547 Detrusor hyperreflexia LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) BE (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005523-42 Sponsor Protocol Number: 905-EC-005 Start Date*: 2007-09-05
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A randomized, double blind, double dummy, placebo controlled study to evaluate the efficacy and safety of solifenacin succinate (5 and 10mg once daily) against placebo and oxybutynin hydrochloride ...
    Medical condition: Neurogenic detrusor overactivity.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) CZ (Completed) NL (Completed) GB (Completed) HU (Completed) FR (Completed) DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-000330-11 Sponsor Protocol Number: 905-CL-047 Start Date*: 2012-02-09
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Phase 3, Open-Label, Baseline-controlled, Multicenter, Sequential Dose Titration Study to Assess the Long-Term Efficacy and Safety, and the Pharmacokinetics of Solifenacin Succinate Suspension in...
    Medical condition: Neurogenic Detrusor Overactivity (NDO)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004857 10012547 Detrusor hyperreflexia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) NL (Completed) DK (Completed) DE (Completed) FR (Ongoing) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-002663-11 Sponsor Protocol Number: PSD506-OAB-002 Start Date*: 2006-10-17
    Sponsor Name:Plethora Solutions Limited
    Full Title: An open-label, escalating dose, proof of concept study to determine the effects of single oral doses of PSD506 on unstable urinary bladder contractions induced by volume provocation in subjects wit...
    Medical condition: Unstable urinary bladder contractions induced by volume provocation in subjects with detrusor hyper-reflexia secondary to spinal injuries above T12.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003159-12 Sponsor Protocol Number: 8405011 Start Date*: 2012-09-24
    Sponsor Name:APOGEPHA Arzneimittel GmbH
    Full Title: Efficacy of propiverine hydrochloride extended release (ER) 45 mg in patients with neurogenic detrusor overactivity – an active-controlled single center crossover trial
    Medical condition: neurogenic detrusor overactivity
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004857 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023210-31 Sponsor Protocol Number: Y52-52120-155 Start Date*: 2012-02-24
    Sponsor Name:Ipsen Innovation
    Full Title: A PHASE IIA, MULTICENTRE, DOUBLE BLIND, SINGLE DOSE, PARALLEL GROUP, PLACEBO CONTROLLED, CLINICAL PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SINGLE DOSE, INTRA-DETRUSOR INJECTIONS OF 750 UNIT...
    Medical condition: NEUROGENIC DETRUSOR OVERACTIVITY
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004857 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed) LT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-000250-28 Sponsor Protocol Number: 905-CL-079 Start Date*: 2011-11-15
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A Multicenter, Open-label, Single-dose Study to Evaluate Pharmacokinetics, Safety and Tolerability of Solifenacin Succinate Suspension in Pediatric Subjects from 5 to less than 18 years of age with...
    Medical condition: Neurogenic Detrusor Overactivity (NDO)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10012547 Detrusor hyperreflexia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-002904-14 Sponsor Protocol Number: C14101 Start Date*: 2019-06-03
    Sponsor Name:Pharming Technologies B.V.
    Full Title: A Phase I/II, Open Label, Proof of Concept Study to investigate Tolerability and Safety of Treatment with Recombinant Human C1 Inhibitor in Patients with Preeclampsia.
    Medical condition: Preeclampsia
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000700-26 Sponsor Protocol Number: 178-CL-203 Start Date*: 2015-09-23
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A multicentre, open-label, single dose, phase 1 study to evaluate the pharmacokinetics, safety and tolerability of mirabegron oral suspension in pediatric subjects from 3 to less than 12 years of a...
    Medical condition: -neurogenic detrusor overactivity (NDO) -overactive bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004857 10012547 Detrusor hyperreflexia LLT
    19.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2006-006872-39 Sponsor Protocol Number: DIMS4 Start Date*: 2008-01-04
    Sponsor Name:Daval International Limited
    Full Title: A randomised, double-blind, placebo controlled study of AIMSPRO in Multiple Sclerosis
    Medical condition: Overactive Bladder in Secondary Progressive Multiple Sclerosis and the other neurological symptoms associated with Secondary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063400 Secondary progressive multiple sclerosis LLT
    9.1 10059617 Overactive bladder LLT
    9.1 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000340-15 Sponsor Protocol Number: 178-CL-202 Start Date*: 2014-07-11
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: A multicentre, open-label, single ascending dose Phase 1 study to evaluate the pharmacokinetics, safety and tolerability of mirabegron OCAS tablets in pediatric subjects from 5 to less than 18 year...
    Medical condition: -neurogenic detrusor overactivity (NDO) -overactive bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10012547 Detrusor hyperreflexia LLT
    16.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) NO (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-005455-37 Sponsor Protocol Number: 178-CL-207 Start Date*: 2022-11-14
    Sponsor Name:Astellas Pharma Global Development Inc.
    Full Title: A Phase 3, Open Label, Multicenter, Baseline-Controlled Sequential Dose Titration Study Followed by a Fixed Dose Observation Period to Evaluate Pharmacokinetics, Efficacy and Safety of Mirabegron P...
    Medical condition: Neurogenic detrusor overactivity (NDO)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10012547 Detrusor hyperreflexia LLT
    23.1 100000004857 10059617 Overactive bladder LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002876-25 Sponsor Protocol Number: 178-CL-206A Start Date*: 2016-03-30
    Sponsor Name:Astellas Pharma Europe B.V.
    Full Title: An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children...
    Medical condition: Neurogenic detrusor overactivity (NDO)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004857 10012547 Detrusor hyperreflexia LLT
    20.0 100000004857 10059617 Overactive bladder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) LT (Completed) NO (Completed) BE (Completed) SK (Completed) RO (Completed) LV (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2009-018157-23 Sponsor Protocol Number: D0490C00014 Start Date*: 2010-11-30
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics ...
    Medical condition: Multiple system atrophy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064060 Multiple system atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) AT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 04:24:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA